Rivaroxaban is a new type of anticoagulant drug, which can be used for the prevention and treatment of pulmonary embolism and postoperative thrombosis of knee joints with good therapeutic effect. Rivaroxaban mainly inhibits factor Xa, which is the newest anticoagulant in the clinic with stable anticoagulant effect, and there is no need to monitor the prothrombinogen time in the process of taking the drug, so the risk of bleeding is relatively low. The main indication of rivaroxaban is the prevention of postoperative venous thrombosis of the knee joint, and it can also be used for the treatment of deep vein thrombosis of the lower extremities, and it can also be used for the treatment of pulmonary embolism. The main adverse reaction of rivaroxaban is bleeding, commonly skin mucous membrane, gum bleeding, nose bleeding, etc., a few patients can occur in the digestive tract and brain bleeding. Allergy to drug components, active bleeding, lactating and pregnant women, patients with severe renal impairment are prohibited. Specific medication needs to be under the guidance of a professional physician.